



NATIONAL HEMOPHILIA FOUNDATION
for all bleeding disorders

January 20, 2000

2029 '00 JAN 24 A9:11

Board of Directors

Officers

Edward Jones, President
Team One Realtors
Tulsa, Oklahoma

Calvin Price, Vice President
Regence Blue Cross Blue Shield
Midvale, Utah

Andrew Voegtli, Treasurer
Appraisal Research Corporation
Brighton, Michigan

Lisa Fullam, Secretary
Fullam & Associates
Scottsdale, Arizona

Directors

Roger Ailes
FOX News
New York, New York

Carolyn Arnold, ScD
University of Massachusetts
Brookline, Massachusetts

Bob Beran
Bell Atlantic
Great Falls, Virginia

Edward Burke
Olsten Health Services
Palm Harbor, Florida

Michael Coyne, MD
Berkshire Medical Center
Pittsfield, Massachusetts

Mark Deneen
SFO Communications
San Francisco, California

Paula Elbirt, MD
Mount Sinai Medical Center
New York, New York

Fred Ferguson
PR Newswire
New York, New York

Elizabeth Fung, MSW, PhD
Children's Memorial Hospital
Chicago, Illinois

Gregory Kerfoot
Sears, Roebuck and Co.
Naperville, Illinois

Jordan Lurie, MD
Loyola University Medical Center
Wheaton, Illinois

Jeanne Lusher, MD
Children's Hospital of Michigan
Rochester Hills, Michigan

Beatrice Pierce, RN, MSN
Rancho Santa Fe, California

Carlos Ruiz
Miami VA Medical Center
Hialeah, Florida

Mark Skinner
American Insurance Association
Houston, Texas

Christopher Vacano
Seattle, Washington

Jan van Eys, PhD, MD
Vanderbilt University School
of Medicine
Nashville, Tennessee

Jill Williams Moberly
Hirons & Company
Bloomington, Indiana

Shirley Wilson
Hemophilia Foundation
of Minnesota and the Dakotas
Ramsey, Minnesota

Stephen E. Bajardi
Executive Director and CEO

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Re: Guidance for Industry: Application of Current Statutory Authority to
Nucleic Acid Testing of Pooled Plasma

Dear Sir/Madam:

Thank you very much for the opportunity to allow the National Hemophilia Foundation (NHF) to submit comments on this draft guidance for industry. NHF is quite pleased with the proposal and would like to respond with its support.

The NHF has long supported regulations mandating the use of nucleic acid testing (NAT) for blood donor and plasma pool screening. We believe that there is ample scientific evidence to support the contention that viral antigen testing alone may fail to identify potentially infectious products due to low levels of virus that may be present in plasma during the window periods of early infection or in a late chronic carrier stage. Because of its superior sensitivity, NAT can reduce the window periods for HIV and HBV and detect potentially infectious units from donors who test seronegative by currently available antigen testing criteria. NAT may especially important for the detection of hepatitis C- and parvovirus B19-contaminated donations, blood-borne diseases for which viral antigen testing is not currently available.

Currently, several manufacturers of plasma derivatives in the United States and Europe have voluntarily begun to employ NAT, often as an additional lot-release test, to further increase the safety of their products. The NHF agrees with the FDA's position that final container testing is not likely to be as sensitive as the testing of individual donations or smaller pools. Further, final container testing may lead to the unnecessary destruction of large plasma pools and does not easily permit donor identification.

99D-4577

C3




NATIONAL HEMOPHILIA FOUNDATION


for all bleeding disorders

As for any biological testing, a variety of quality control procedures are required to assure effectiveness, reproducibility and safety in the specific application for which their use is intended. For this reason, the NHF supports the FDA's position that NAT testing procedures and kits should be licensed and subject to standard regulation and oversight. The NHF recognizes that the optimal size of the pool appropriate for NAT remains to be determined. Nonetheless, we agree with the FDA's position that the identification of virus-positive donors is extremely important, not just to improve the safety of the blood supply, but in order to offer appropriate counseling, treatment and blood donation deferral. We also recognize that objections have been raised concerning the application of NAT due to concerns of cost-effectiveness. However, we maintain that industry has the obligation to implement the best available procedures to ensure the safety of the blood supply and these should be subject to FDA regulation and oversight.

In conclusion, we wish to reiterate NHF's support for this draft guidance and applaud the FDA for its furtherance of the technology to ensure the integrity and safety of the nation's blood supply.

Sincerely,


Stephen E. Bajardi
Executive Director & CEO


Bruce M. Ewenstein, M.D., Ph.D.
Co-Chair
NHF Blood Safety Working Group

SB/BME/pc

Board of Directors

Officers

Edward Jones, President
Team One Realtors
Tulsa, Oklahoma

Calvin Price, Vice President
Regence Blue Cross Blue Shield
Midvale, Utah

Andrew Voegtle, Treasurer
Appraisal Research Corporation
Brighton, Michigan

Lisa Fullam, Secretary
Fullam & Associates
Scottsdale, Arizona

Directors

Roger Ailes
FOX News
New York, New York

Carolyn Arnold, ScD
University of Massachusetts
Brookline, Massachusetts

Bob Beran
Bell Atlantic
Great Falls, Virginia

Edward Burke
Olsten Health Services
Palm Harbor, Florida

Michael Coyne, MD
Berkshire Medical Center
Pittsfield, Massachusetts

Mark Deneen
SFO Communications
San Francisco, California

Paula Elbirt, MD
Mount Sinai Medical Center
New York, New York

Fred Ferguson
PR Newswire
New York, New York

Elizabeth Fung, MSW, PhD
Children's Memorial Hospital
Chicago, Illinois

Gregory Kerfoot
Sears, Roebuck and Co.
Naperville, Illinois

Jordan Lurie, MD
Loyola University Medical Center
Wheaton, Illinois

Jeanne Lusher, MD
Children's Hospital of Michigan
Rochester Hills, Michigan

Beatrice Pierce, RN, MSN
Rancho Santa Fe, California

Carlos Ruiz
Miami VA Medical Center
Hialeah, Florida

Mark Skinner
American Insurance Association
Houston, Texas

Christopher Vacano
Seattle, Washington

Jan van Eys, PhD, MD
Vanderbilt University School
of Medicine
Nashville, Tennessee

Jill Williams Moberly
Hirons & Company
Bloomington, Indiana

Shirley Wilson
Hemophilia Foundation
of Minnesota and the Dakotas
Ramsey, Minnesota

Stephen E. Bajardi
Executive Director and CEO

116 West 32nd Street • 11th Floor
New York, NY 10001

(800) 42-HANDI • (212) 328-3700 • fax (212) 328-3777

www.hemophilia.org • info@hemophilia.org


FedEx USA Airbill FedEx Tracking Number

8156 8910 0031

Form
ID No.

0215

Recipient's Copy

1 From This portion can be removed for Recipient's records.Date _____ FedEx Tracking Number **815689100031**Sender's Name **Patrick Collins** Phone **212 328-3700**Company **NATIONAL HEMOPHILIA FOUNDATION**Address **116 W 32ND ST FL 11** Dept./Floor/Suite/Room _____City **NEW YORK** State **NY** ZIP **10001****2 Your Internal Billing Reference****3 To**
Recipient's Name **Docket's Management Branch** Phone **301 827-0795**Company **Food and Drug Administration**Address **5630 Fishers Lane Room 1061** Dept./Floor/Suite/Room _____
We cannot deliver to P.O. boxes or P.O. ZIP codes.To "HOLD" at FedEx location,
print FedEx address here.City **Rockville** State **MD** ZIP **20852**

1110453182

4a Express Package Service☒ **FedEx Priority Overnight**
Next business morning☐ **FedEx Standard Overnight**
Next business afternoon**Packages up to 150 lbs.**
Delivery commitment may be later in some areas.
☐ **FedEx First Overnight**
Earliest next business morning
delivery to select locations☐ **FedEx 2Day***
Second business day☐ **FedEx Express Saver***
Third business day* FedEx Letter Rate not available
Minimum charge: One-pound rate**4b Express Freight Service**☐ **FedEx 1Day Freight***
Next business day☐ **FedEx 2Day Freight**
Second business day**Packages over 150 lbs.**
Delivery commitment may be later in some areas.
☐ **FedEx 3Day Freight**
Third business day* Call for Confirmation* Declared value limit \$500**5 Packaging**☒ **FedEx Letter***☐ **FedEx Pak***☐ **Other Pkg.**
Includes FedEx box, FedEx
tapes, and customer pkg.**6 Special Handling**☐ **Saturday Delivery**
Available for FedEx Priority
Overnight and FedEx 2Day
to select ZIP codes☐ **Sunday Delivery**
Available for FedEx Priority
Overnight to select ZIP codes☒ **HOLD Weekday**
at FedEx Location
Not available with
FedEx First Overnight☐ **HOLD Saturday**
at FedEx Location
Available for FedEx Priority
Overnight and FedEx 2Day
to select locations**Does this shipment contain dangerous goods?**
One box must be checked.☐ **No**☐ **Yes**
As per attached
Shipper's Declaration☐ **Yes**
Shipper's Declaration
not required☐ **Dry Ice**
Dry Ice, 9, UN 1845☐ **Cargo Aircraft Only****7 Payment Bill to:** Enter FedEx Acct. No. or Credit Card No. below.☒ **Sender**
Acct. No. in Section
1 will be billed.☐ **Recipient**☐ **Third Party**☐ **Credit Card**☐ **Cash/Check**
Obtain Recip.
Acct. No.

Total Packages

Total Weight

Total Charges

Credit Card Auth.

*Our liability is limited to \$100 unless you declare a higher value. See the FedEx Service Guide for details.**8 Release Signature**Sign to authorize delivery without obtaining signature.By signing you authorize us to deliver this shipment without obtaining a signature
and agree to indemnify and hold us harmless from any resulting claims.**Questions? Call 1-800-Go-FedEx** (800-463-3339)
Visit our Web site at www.fedex.com
SRS 739 • Rev. Date 11/98 • Part #1549135 • ©1999-98 FedEx • PRINTED IN U.S.A.

359